Medivir scraps pancreatic cancer program; Ambrx recruits Amgen vet as new CMO;

@FierceBiotech: ICYMI yesterday: J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex. Report | Follow @FierceBiotech

@JohnCFierce: Catalent stops production at French plant, brings in law enforcement after it twice detects tampering. FiercePharma story | Follow @JohnCFierce

@DamianFierce: Fun reminder of pharma's insane margins: $NVS has a Map My Run ad for a multiple sclerosis drug. Item | Follow @DamianFierce

> Sweden's Medivir is scrapping its ADAM8 inhibitor program for pancreatic cancer. And its licensing agreement with Cancer Research Technology is being thrown out alongside the program. Release

> Ambrx, 6 months removed from being acquired by a group of Chinese drugmakers, has recruited Amgen ($AMGN) veteran Yong-Jiang Hei to serve as its chief medical officer. More

> The U.K.'s Cell Therapy Catapult has begun construction of its cell and gene therapy manufacturing center. Release

Medical Device News

@FierceMedDev: Crime syndicates are hacking devices to steal private medical information for profit. ICYMI last week | Follow @FierceMedDev

@EmilyWFierce: calling for more regulation of lab-developed tests prior to congressional hearing today. More from the WSJ | Follow @EmilyWFierce

> SI-Bone gets $39M+ in debt to market joint fusion implant system. Story

> FDA approves, Medtronic launches the first remote monitoring pacemaker app. Report

> Diagnostics companies jump into rapidly growing market for point-of-care superbug tests. Article

Pharma News

@FiercePharma: Indonesia's Kalbe and South Korea's Genexine link up for biomedical work. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: There are lots of changes going on among generics producers but here are the top players. Feature | Follow @EricPFierce

> J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price. Report

> Can Valeant win without big price hikes? Early Addyi scripts aren't a good sign. More

> U.S. lawmakers step up drug-pricing probes, add Valeant pharmacy to their target list. Article

Pharma Manufacturing News

> Top Novartis exec in India says two plants warned by FDA completing remediation. Item

> Baxter Singapore plant gets FDA OK to produce Advate hemophilia product. More

> Valeant adds recall to long list of problems. Article

> Regulator halts Catalent production at French plant where product sabotage suspected. Report

> Four Roche plants go up for sale in move to more high-potency, targeted drugs. Story

Drug Delivery News

> NC State team: Gold nanoparticles can control the shape of DNA, RNA. Report

> Avedro bags $32M in financing to expand use of its drug delivering ophthalmology platform. More

> Egalet announces patent for its abuse-deterrence platform. Item

> Swiss scientists take a look inside 'cubosomes' for drug delivery potential. Story

> RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. Article

Pharma Asia News

> Lee's Pharma affiliate licenses Tragara's TG02 oncology treatment for much of Asia. Story

> Indian drugmakers eye Japanese market for acquisitions. Report

> India looks to push development of biotech startups. More

> HK-based Chi-Med takes another regulatory step to Nasdaq listing. Article

> Australia's Mesoblast formally lists on Nasdaq. Item

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.